NERV has been granted a new patent
Jun 26, 2024, 10:35 PM
0.65%
What does NERV do
Minerva Neurosciences, a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focuses on developing treatments for CNS diseases, with leading candidates roluperidone for schizophrenia and MIN-301 for Parkinson's. Established in 2014, the company also advances seltorexant for insomnia and MDD while employing nine full-time staff.
NERV filed a patent for "use of roluperidone in preventing relapse in schizophrenia patients" on Mon, February 13, 2023. The patent was officially published on Thu, August 17, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.